Literature DB >> 25366013

Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms.

Koji Tamai1, Ryo Tachikawa, Kyoko Otsuka, Hiroyuki Ueda, Yuji Hosono, Keisuke Tomii.   

Abstract

We herein report a patient with clinically amyopathic dermatomyositis (CADM) who developed anti-CADM-140 autoantibody in association with rapidly progressive interstitial lung disease (RP-ILD). Chest high-resolution computed tomography (HRCT) revealed early pulmonary involvement preceding typical cutaneous lesions. Primary lesions of patchy peribronchial opacity developed ground-glass opacity and consolidation with architectural distortion and traction bronchiectasis. The possibility of anti-CADM-140 autoantibody-associated RP-ILD should be considered when patchy peribronchial opacity of an unknown cause is visible on chest HRCT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25366013     DOI: 10.2169/internalmedicine.53.2769

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report.

Authors:  Maria L Mihailescu; Cuoghi Edens; Mark D Hoffman
Journal:  Case Rep Dermatol       Date:  2021-04-19

2.  The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.

Authors:  Takeshi Osawa; Kozo Morimoto; Yuka Sasaki; Shuichi Matsuda; Kazunari Yamana; Ryozo Yano; Takashi Uchiyama; Hajime Goto
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

3.  Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations.

Authors:  Junichi Aoyama; Hiroki Hayashi; Chika Yajima; Hiroyuki Takoi; Toru Tanaka; Takeru Kashiwada; Nariaki Kokuho; Yasuhiro Terasaki; Ayumi Nishikawa; Takahisa Gono; Masataka Kuwana; Yoshinobu Saito; Shinji Abe; Masahiro Seike; Akihiko Gemma
Journal:  Respir Med Case Rep       Date:  2019-01-14

4.  Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease:A case report.

Authors:  Hiroyuki Kagawa; Kazuyuki Tsujino; Yuji Yamamoto; Ami Iwai; Reina Hara; Takanori Matsuki; Kiyoharu Fukushima; Yohei Oshitani; Kenji Yoshimura; Mari Miki; Keisuke Miki; Seigo Kitada; Masahide Mori; Hiroshi Kida
Journal:  Respir Med Case Rep       Date:  2020-02-01

5.  Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.

Authors:  Noriho Sakamoto; Hiroshi Ishimoto; Shota Nakashima; Hirokazu Yura; Takuto Miyamura; Daisuke Okuno; Atsuko Hara; Takeshi Kitazaki; Tomoyuki Kakugawa; Yuji Ishimatsu; Minoru Satoh; Hiroshi Mukae
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

Review 6.  Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.

Authors:  Juan González-Moreno; Manuel Raya-Cruz; Ines Losada-Lopez; Ana Paula Cacheda; Cristina Oliver; Bartomeu Colom
Journal:  Rheumatol Int       Date:  2018-02-07       Impact factor: 2.631

7.  Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.

Authors:  Chenjia He; Wenyu Li; Qibing Xie; Geng Yin
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.